Thakral succeeds Interim CEO, Peter M. Neupert, who will remain chairman of the board DURHAM, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that Fortrea’s Board of Directors (the “Board”) named Anshul Thakral as Fortrea’s CEO, effective August 4, 2025. He was also appointed to serve as a director on the Company’s Board, effective as of that date. Thakral succeeds Interim CEO, Peter M. Neupert, who will r ...

Following the recommendation of the IDMC, Spero Therapeutics (NASDAQ: SPRO ) has decided to stop its PIVOT-PO Phase 3 trial early and ahead of schedule. The study's objective of non-inferiority to intravenous imipenem-cilastatin was achieved , although theHey there, I would like to encourage you to follow me and read my articles for stocks with an excellent risk-reward profile. i am an individual who enjoys dealing with public Biotech companys. I write articles not for investment activities, I just want to ...

Globally recognized Oncology Key Opinion Leader, Brian Andrew Van Tine, MD, PhD, discusses the positive topline results from the U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) Watch the “What This Means" segment here HOUSTON, June 11, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors ...

When I covered Black Diamond Therapeutics (NASDAQ: BDTX ) earlier this year , I did not find their decline justified by the facts, particularly in light of upcoming trial readouts in an areaI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space ...

DOVER, Del., June 09, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”) announce that on June 5, 2025 Portage and Compedica Holdings Limited, a company formed under the laws of the Isle of Man (“Compedica”) entered a mutual Subscription Agreement (“Subscription Agreement”). Pursuant to the Subscription Agreement, Portage issued 625,000 ordinary shares at a per share price of $8.00 in exchange ...

– KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 – – KPL-387 Phase 1 single ascending dose data support profile for monthly dosing – – Presentation and webcast at Jefferies 2025 Global Healthcare Conference scheduled for 12:50 pm ET today– LONDON, June 05, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus ...

ICON Public Company (ICLR) FY Conference June 04, 2025 11:40 AM ET Speaker0 Alright. Good morning, everyone, and thanks for joining us today for the management presentation. My name is Max Mach, and I'm the research analyst here at William Blair who covers Icon. We're pleased to be joined this morning by CEO, doctor Steve Cutler, and Kate Haven, vice president, investor relations. Before we get into the presentation, I have to mention two things. First, the breakout session will be held in Adler on the seco ...

On a generally upbeat Monday for the stock market, investors weren't only buying into U.S. companies. Quite a few of them also piled into the American Depositary Receipts (ADRs) of Danish biotech Genmab (GMAB 3.94%), on the back of encouraging news from the laboratory. Management's disclosure of the status of a shareholder-pleasing initiative also helped boost sentiment. The price of those ADRs rose by almost 4% as a result -- quite a distance higher than the S&P 500's (^GSPC 0.41%) 0.4% advance.Fresh news ...

Vera Therapeutics, Inc. VERA saw its share price surge over 65% during the pre-market trading session on Monday after the company released ORIGIN Phase 3 trial data.Participants treated with atacicept for immunoglobulin A nephropathy (IgAN) achieved a 46% reduction from baseline in proteinuria as measured by 24-hour urine protein-to-creatinine ratio (UPCR), with a statistically significant and clinically meaningful 42% reduction in UPCR compared to placebo (p<0.0001) at week 36.Also Read: Kidney Disease-Foc ...

IBI363 Data Update in ASCO; Clearer Path to Success CITI'S TAKE Innovent updated the data of IBI363 in IO-treated NSCLC, CRC and IO- treated advanced acral and mucosal melanoma at ASCO. IBI363 showed strong efficacy in IO-treated sqNSCLC with an ORR of 43.3% (13/30) (cORR 36.7%) and mPFS of 7.3 mo. We think this data could give investors more confidence in IBI363 beating docetaxel (mPFS ~4 mo and mOS 10- 12 mo) in this setting. IBI363 also showed positive data in 3L/+ MSS/pMMR CRC, with an ORR of 23.5% (16/ ...